LANTHEUS HOLDINGS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.81 USD | +2.37% |
|
+4.97% | +2.92% |
| Apr. 18 | B. Riley Raises Price Target on Lantheus Holdings to $99 From $95, Keeps Buy Rating | MT |
| Mar. 07 | Lantheus Holdings Insider Sold Shares Worth $262,005, According to a Recent SEC Filing | MT |
Financials (USD)
| Sales 2024 * | 1.43B | Sales 2025 * | 1.52B | Capitalization | 4.27B |
|---|---|---|---|---|---|
| Net income 2024 * | 331M | Net income 2025 * | 434M | EV / Sales 2024 * | 2.98 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.81 x |
| P/E ratio 2024 * |
13.5
x | P/E ratio 2025 * |
10.5
x | Employees | 834 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.57% |
More Fundamentals
* Assessed data
More news
Latest transcript on Lantheus Holdings, Inc.
More recommendations
More press releases
More news
| 1 day | +2.37% | ||
| 1 week | +4.97% | ||
| Current month | +2.52% | ||
| 1 month | +9.19% | ||
| 3 months | +20.21% | ||
| 6 months | -7.80% | ||
| Current year | +2.92% |
1 week
59.56
65.26
1 month
57.7865.26
Current year
50.2069.73
1 year
50.20100.85
3 years
19.30100.85
5 years
8.67100.85
10 years
1.76100.85
| Managers | Title | Age | Since |
|---|---|---|---|
Brian Markison
CEO | Chief Executive Officer | 64 | 12-08-31 |
Paul Blanchfield
PSD | President | 43 | 20-01-26 |
Robert Marshall
DFI | Director of Finance/CFO | 57 | 18-09-20 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Brian Markison
CEO | Chief Executive Officer | 64 | 12-08-31 |
James H. Thrall
BRD | Director/Board Member | 80 | 18-01-31 |
Sam Leno
BRD | Director/Board Member | 78 | 12-04-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.58% | 16 M€ | -9.75% | ||
| 1.30% | 12 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 62.33 | +1.38% | 1,271,332 |
| 24-04-17 | 61.48 | -0.40% | 537,390 |
| 24-04-16 | 61.73 | +2.46% | 569,974 |
| 24-04-15 | 60.25 | -0.89% | 670,069 |
| 24-04-12 | 60.79 | -1.15% | 654,657 |
Delayed Quote Nasdaq, April 19, 2024 at 04:00 pm EDT
More quotes
Lantheus Holdings, Inc. is a radiopharmaceutical-focused company. The Company is engaged in delivering science to enable clinicians to find, fight and follow disease to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Its Radiopharmaceutical Oncology diagnostics and therapeutic candidates help healthcare professionals (HCPs) find, fight, and follow cancer, with a focus in prostate cancer. Its Precision Diagnostic products assist HCPs to find and follow diseases, with a focus in cardiology. Its Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma solutions platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, NEUROLITE, Xenon-133, CARDIOLITE, RELISTOR, Automated Bone Scan Index, and others. Its commercial products are used by cardiologists, internal medicine physicians, and others.
Calendar
2024-05-02
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
62.33
USD
Average target price
94.11
USD
Spread / Average Target
+50.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +2.92% | 4.27B | |
| -1.04% | 12.47B | |
| -17.29% | 6.99B | |
| -2.21% | 5.1B | |
| -4.79% | 4.27B | |
| -50.07% | 3.45B | |
| +7.65% | 2.61B | |
| -15.92% | 2.08B | |
| -3.34% | 1.67B | |
| -13.66% | 1.48B |
- Stock Market
- Equities
- LNTH Stock
